Compare Mercadolibre Inc (MELI) vs TG Therapeutics Inc (TGTX) Price & Performance

MercadoLibre (MELI) trades at $1,889.85, up 0.91% on the day, with a bullish technical signal and strong analyst support. Revenue grew to $28.89 billion in 2025, though net income margin dipped to 6.91%. The company is expanding its fintech ecosystem, with credit portfolio surging 75% to $16.4 billion in Q2 2026. Operating cash flow remains robust at $12.12 billion, supporting aggressive investment in logistics and market expansion across Latin America.

Outlook is positive given dominant market position and integrated e-commerce-fintech model, but valuation multiples like P/E of 50.51 suggest high growth expectations. Risks include macroeconomic pressures in key markets like Argentina and intense regional competition. Analyst consensus is strongly bullish with a $2,170 price target, indicating ~15% upside from current levels.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.